Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Jun;39(6):692–695.

Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide.

T B Vree 1, M van den Biggelaar-Martea 1, C P Verwey-van Wissen 1
PMCID: PMC1365085  PMID: 7654491

Abstract

The effect of oral probenecid (1 g) on the pharmacokinetics of frusemide (80 mg p.o.) and its acyl glucuronide was studied in nine healthy subjects. Probenecid significantly increased the t1/2,z of frusemide from 2.01 +/- 0.68 to 3.40 +/- 1.48 h (P = 0.0015) and significantly decreased oral clearance from 164 +/- 67.0 to 58.3 +/- 28.1 ml min-1 (P = 0.0001). No effect of probenecid on the plasma protein binding of frusemide was detected. Probenecid significantly increased the tmax of the metabolite frusemide acyl glucuronide from 1.4 to 2.6 h, but had no effect on the tlag, Cmax, t1/2,z and plasma protein binding. The urinary recoveries of unchanged frusemide (39.2 +/- 10.2 vs 34.4 +/- 8.6%, P = 0.28) and its acyl glucuronide (12.1 +/- 2.7 vs 11.8 +/- 3.7%, P > 0.8) were not altered by probenecid. However, probenecid decreased the renal clearance of both frusemide (128 +/- 49 vs 44.0 +/- 18.6 ml min-1, P = 0.0002) and the acyl glucuronide (552 +/- 298 vs 158 +/- 94.0 ml min-1, P < 0.0001). The non-renal clearance of frusemide (36.7 +/- 21.0 vs 15.2 +/- 13.4 ml min-1, P = 0.0068) was also decreased. The clinical relevance of the study relates to the possible conjugation of frusemide in the kidney and the role of the conjugate in the pharmacodynamic effect.

Full text

PDF
692

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreasen F., Mikkelsen E. Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure. Eur J Clin Pharmacol. 1977 Aug 17;12(1):15–22. doi: 10.1007/BF00561400. [DOI] [PubMed] [Google Scholar]
  2. Beermann B., Dalén E., Lindström B., Rosén A. On the fate of furosemide in man. Eur J Clin Pharmacol. 1975 Oct 10;9(1):51–61. doi: 10.1007/BF00613429. [DOI] [PubMed] [Google Scholar]
  3. Benet L. Z. Pharmacokinetics/pharmacodynamics of furosemide in man: a review. J Pharmacokinet Biopharm. 1979 Feb;7(1):1–27. doi: 10.1007/BF01059438. [DOI] [PubMed] [Google Scholar]
  4. Benet L. Z., Smith D. E., Lin E. T., Vincenti F., Gambertoglio J. G. Furosemide assays and disposition in healthy volunteers and renal transplant patients. Fed Proc. 1983 Apr;42(6):1695–1698. [PubMed] [Google Scholar]
  5. Brater D. C. Effects of probenecid on furosemide response. Clin Pharmacol Ther. 1978 Nov;24(5):548–554. doi: 10.1002/cpt1978245548. [DOI] [PubMed] [Google Scholar]
  6. Chennavasin P., Seiwell R., Brater D. C., Liang W. M. Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kidney Int. 1979 Aug;16(2):187–195. doi: 10.1038/ki.1979.120. [DOI] [PubMed] [Google Scholar]
  7. Chennavasin P., Seiwell R., Brater D. C. Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man. J Pharmacol Exp Ther. 1980 Oct;215(1):77–81. [PubMed] [Google Scholar]
  8. Faed E. M. Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab Rev. 1984;15(5-6):1213–1249. doi: 10.3109/03602538409033562. [DOI] [PubMed] [Google Scholar]
  9. Hammarlund-Udenaes M., Benet L. Z. Furosemide pharmacokinetics and pharmacodynamics in health and disease--an update. J Pharmacokinet Biopharm. 1989 Feb;17(1):1–46. doi: 10.1007/BF01059086. [DOI] [PubMed] [Google Scholar]
  10. Ponto L. L., Schoenwald R. D. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I). Clin Pharmacokinet. 1990 May;18(5):381–408. doi: 10.2165/00003088-199018050-00004. [DOI] [PubMed] [Google Scholar]
  11. Proost J. H., Meijer D. K. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med. 1992 May;22(3):155–163. doi: 10.1016/0010-4825(92)90011-b. [DOI] [PubMed] [Google Scholar]
  12. Rachmel A., Hazelton G. A., Yergey A. L., Liberato D. J. Furosemide 1-O-acyl glucuronide. In vitro biosynthesis and pH-dependent isomerization to beta-glucuronidase-resistant forms. Drug Metab Dispos. 1985 Nov-Dec;13(6):705–710. [PubMed] [Google Scholar]
  13. Smith D. E., Benet L. Z. Biotransformation of furosemide in kidney transplant patients. Eur J Clin Pharmacol. 1983;24(6):787–790. doi: 10.1007/BF00607088. [DOI] [PubMed] [Google Scholar]
  14. Smith D. E., Gee W. L., Brater D. C., Lin E. T., Benet L. Z. Preliminary evaluation of furosemide-probenecid interaction in humans. J Pharm Sci. 1980 May;69(5):571–575. doi: 10.1002/jps.2600690526. [DOI] [PubMed] [Google Scholar]
  15. Smith D. E., Lin E. T., Benet L. Z. Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay. Drug Metab Dispos. 1980 Sep-Oct;8(5):337–342. [PubMed] [Google Scholar]
  16. Vree T. B., Beneken Kolmer E. W. Direct measurement of probenecid and its glucuronide conjugate by means of high pressure liquid chromatography in plasma and urine of humans. Pharm Weekbl Sci. 1992 Jun 19;14(3):83–87. doi: 10.1007/BF01962691. [DOI] [PubMed] [Google Scholar]
  17. Vree T. B., Van Den Biggelaar-Martea M., Verwey-Van Wissen C. P., Vree M. L., Guelen P. J. The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. Br J Clin Pharmacol. 1993 May;35(5):467–472. doi: 10.1111/j.1365-2125.1993.tb04171.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Vree T. B., Van Ewijk-Beneken Kolmer E. W., Wuis E. W., Hekster Y. A. Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study. Pharm Weekbl Sci. 1992 Oct 16;14(5):325–331. doi: 10.1007/BF01977622. [DOI] [PubMed] [Google Scholar]
  19. Vree T. B., Van den Biggelaar-Martea M., Van Ewijk-Beneken Kolmer E. W., Hekster Y. A. Probenecid inhibits the renal clearance and renal glucuronidation of nalidixic acid. A pilot experiment. Pharm World Sci. 1993 Aug 20;15(4):165–170. doi: 10.1007/BF01880560. [DOI] [PubMed] [Google Scholar]
  20. Vree T. B., van den Biggelaar-Martea M., Verwey-van Wissen C. P. Determination of furosemide with its acyl glucuronide in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis with fluorescence detection. Preliminary pharmacokinetics and effect of probenecid. J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):53–62. doi: 10.1016/0378-4347(94)00093-x. [DOI] [PubMed] [Google Scholar]
  21. Vree T. B., van den Biggelaar-Martea M., Verwey-van Wissen C. P., van Ewijk-Beneken Kolmer E. W. Probenecid inhibits the glucuronidation of indomethacin and O-desmethylindomethacin in humans. A pilot experiment. Pharm World Sci. 1994 Feb 18;16(1):22–26. doi: 10.1007/BF01870935. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES